A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor-Reference-Cited by-同舟云学术

A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor

Published:2019-05 Issue:5 Volume:80 Page:1451-1453
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Pao-Ling Lin Christine,Gordon Samantha,Her Min Ji,Rosmarin David

Publisher

Elsevier BV

Subject

Dermatology

Reference2 articles.

1. Nankervis H, Thomas KS, Delamere FM, et al. Scoping systematic review of treatments for eczema. Southampton (UK): NIHR Journals Library; 2016 May. (Programme Grants for Applied Research, No. 4.7.) Chapter 4, Topical corticosteroids and topical immunomodulators. Available from: https://www.ncbi.nlm.nih.gov/books/NBK363131/. Accessed July 16, 2018.

2. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults;Paller;J Am Acad Dermatol,2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Atopic Dermatitis in Children;Cureus;2024-09-14

2. Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor;Indian Journal of Dermatology;2024-09-13

3. Biologic and Small Molecule Therapy in Atopic Dermatitis;Biomedicines;2024-08-13

4. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies;Journal of Dermatological Treatment;2024-01-31

5. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis;Dermatology;2023-12-11